<DOC>
	<DOCNO>NCT02141425</DOCNO>
	<brief_summary>The purpose study assess safety , tolerability pharmacokinetics single ascend dos ASP015K .</brief_summary>
	<brief_title>A Study Assess Safety , Tolerability Pharmacokinetics ASP015K Healthy Subjects</brief_title>
	<detailed_description>Subjects enrol 1 3 dose cohort ( low , medium high ) . Each cohort consist 8 subject 3:1 randomization ratio ASP015K placebo . Subjects confine clinic study procedure day 4 ( 5 day ) . After subject dose cohort complete study procedure day 4 , decision make whether dose enrollment next dose cohort occur , take place review safety tolerability data day 4 recent dose cohort additional report adverse event ( AEs ) previously dose cohort .</detailed_description>
	<criteria>Female subject must either : Of nonchildbearing potential : 1. postmenopausal ( define least 1 year without menses ) prior screen , 2. document surgically sterile status posthysterectomy ( least 1 month prior screen ) . Or , childbearing potential : 1. must negative pregnancy test screen day 1 . 2. must use highly effective contraception consist 2 form birth control ( 1 must barrier method ) start screen throughout study period 90 day final study drug administration . Female subject must donate ovum start screen throughout study period , 90 day final study drug administration . Male subject female spouse/partner childbearing potential must use highly effective contraception consist 2 form birth control ( 1 must barrier method ) start screen continue throughout study period , 90 day final study drug administration . Male subject must donate sperm start screen continue throughout study period , 90 day final study drug administration . Subject Body Mass Index ( BMI ) range 18.5 32.0 kg/m2 , inclusive , must weigh least 50 kg screening . Subject must capable swallow multiple ( 20 ) tablet . Subject agree participate another investigational study treatment . Female subject pregnant within 6 month screen assessment breast feeding within 3 month screen . Subject know suspected hypersensitivity ASP015K component formulation use . Subject liver function test ( aspartate aminotransferase , alanine aminotransferase , alkaline phosphatase , gammaglutamyl transferase total bilirubin ) ULN screen day 1 . If result outside limit , assessment may repeat screen day 1 . Subject clinically significant history allergic condition . Subject history evidence clinically significant cardiovascular , gastrointestinal ( GI ) , endocrinologic , hematologic , hepatic , immunologic , metabolic , urologic , pulmonary , neurologic , dermatologic , psychiatric , renal and/or major disease malignancy , judge investigator designee . Subject has/had febrile illness symptomatic , viral , bacterial ( include upper respiratory infection ) fungal ( noncutaneous ) infection within 1 week prior day 1 . Subject clinically significant abnormality follow investigator 's review physical examination , electrocardiogram ( ECG ) protocoldefined clinical laboratory test screen day 1 . Subject mean pulse &lt; 40 &gt; 90 beat per minute , mean systolic blood pressure ( BP ) &gt; 140 mmHg mean diastolic BP &gt; 90 mmHg ( measurement take triplicate subject rest sit position 5 minute ) screen day 1 . Subject mean QTcF interval &gt; 430 msec ( male ) &gt; 450 msec ( female ) screen day 1 . If mean QTcF exceed limit , 1 additional triplicate ECG take . If triplicate also give abnormal result , subject exclude . Subject use prescribe nonprescribed drug ( include vitamin , natural herbal remedy , e.g. , St. John 's Wort ) 2 week prior study drug administration , exception hormone replacement therapy ( HRT ) , hormonal contraceptive intermittent acetaminophen ( 2g per day ) . Subject smoke used tobaccocontaining product nicotine nicotinecontaining product past 6 month prior screen . Subject history consume 14 unit alcoholic beverage per week within 6 month prior screen history alcoholism drug/chemical substance abuse within past 2 year prior screen ( Note : 1 unit = 12 ounce beer , 4 ounce wine 1 ounce spirit ) . Subject positive test alcohol , drug abuse cotinine screen day 1 . Subject anticipate inability abstain xanthine ( e.g. , caffeine ) , grapefruit , Seville orange ( include marmalade ) , star fruit product contain item 72 hour prior day 1 throughout duration study . Subject use inducer metabolism ( e.g. , barbiturate , rifampin ) 3 month prior day 1 . Subject significant blood loss , donate 1 unit ( 450 mL ) blood , receive transfusion blood blood product within 60 day donate plasma within 7 day prior day 1 . Subject positive test hepatitis B surface antigen , antihepatitis A virus ( Immunoglobulin M ) antibody , antihepatitis C virus antibody , hepatitis B core antibody antihuman immunodeficiency virus Type 1 Type 2 screening . Subject positive tuberculosis skin test , Quantiferon Gold® TSPOT® test screening . Subject receive vaccine within 60 day prior study drug administration . Subject absolute neutrophil count ( ANC ) &lt; 2000 cells/mm3 creatine phosphokinase ( CPK ) &gt; 1.5 x ULN screen day 1 . If result outside limit , assessment may repeat screen day 1 . Subject major GI surgery medical condition may inhibit absorption and/or metabolism study drug . Subject participate interventional clinical study treat investigational drug within 30 day 5 halflives drug , whichever longer , prior screen . Subject condition , opinion investigator , preclude subject 's participation study . Subject employee Astellas Group , Janssen Pharmaceuticals vendor involve study . Subject participate prior study ASP015K .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Healthy volunteer</keyword>
	<keyword>ASP015K</keyword>
</DOC>